Discovery Laboratorie Kauf zu 2,30 $ Ziel 2,55 €
Seite 1 von 4 Neuester Beitrag: 30.12.10 12:01 | ||||
| Eröffnet am: | 24.10.07 19:33 | von: Jäger u Sam. | Anzahl Beiträge: | 93 |
| Neuester Beitrag: | 30.12.10 12:01 | von: CosmicTrade | Leser gesamt: | 9.850 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < 1 | 2 | 3 | 4 4 > | ||||
Jäger u Sammler
Optionen
| Boardmail an "Jäger u Sammler" |
Wertpapier: Windtree Therapeutics |
gryneus.jpg
MFG
Chali
Optionen
| Boardmail an "Chalifmann3" |
Wertpapier: Windtree Therapeutics |
http://www.streetinsider.com/Corporate+News/...t+Hearing/6141584.html
Optionen
| Boardmail an "brunneta" |
Wertpapier: Windtree Therapeutics |
Leading Proxy Advisory Firms Recommend that Discovery Labs’ Stockholders Vote “FOR” Important Proposals at Annual Meeting of Stockholders
December 7, 2010
Discovery Labs Aerosurf® Improves Lung Function and Reduces Inflammation in a Dose-dependent Fashion in Established Non-Clinical Model of Preterm Respiratory Distress Syndrome
http://www.discoverylabs.com/home.php
Optionen
| Boardmail an "brunneta" |
Wertpapier: Windtree Therapeutics |
NIH Awards Discovery Labs Fast Track SBIR Grant to Support Development of Aerosolized KL4 Surfactant
Date : 12/16/2010 @ 7:00AM
Source : GlobeNewswire Inc.
Stock : Discovery Laboratories, Inc. (DSCO)
http://ih.advfn.com/p.php?pid=nmona&article=45679721
Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS). The Company submitted a proposal, with a total budget of $2.4 million, for the development of the Company's proprietary capillary aerosol generating (CAG) device technology followed by a Phase 2a clinical trial of aerosolized KL4 surfactant in preterm infants with or at risk for RDS. The Phase I grant provides $580,000 to support development efforts. The Company anticipates the potential awarding of the Phase II grant, up to an additional $1.8 million, following the conclusion of Phase I activities.
Dr. Robert Segal, Discovery Labs' Senior Vice President and the Grant Principal Investigator commented, "We are extremely pleased that the NIH has recognized the importance of our aerosolized KL4 surfactant technology, which has the potential to significantly improve the management of preterm infants with or at risk for RDS and make it possible for many more preterm infants to be treated with surfactant therapy."
RDS is one of the most prevalent medical issues facing premature infants in the neonatal intensive care unit and is a condition in which premature infants are born with a lack of natural lung surfactant and are unable to breathe. Approximately 360,000 low birth weight premature infants are born annually in the United States and at risk for RDS. Premature babies with RDS often require endotracheal intubation and mechanical ventilation. In many cases, currently available animal-derived surfactants are administered while the child is intubated. Neonatologists often try to avoid intubation and mechanical ventilation in preterm infants due to well established medical risks associated with these procedures. As a result, many neonatologists reserve intubation for infants with severe respiratory distress, where the benefits of invasive procedures clearly outweigh the associated risks. The Company believes that the neonatal medical community increasingly recognizes the potential benefits of a synthetic, peptide-containing surfactant, and a less-invasive method of delivering surfactant, such as aerosolized KL4 surfactant.
KL4 surfactant is a completely synthetic, peptide-containing surfactant designed to closely mimic the essential attributes of human lung surfactant. Discovery Labs is developing aerosolized KL4 surfactant for delivery in conjunction with non-invasive nasal continuous positive airway pressure (nCPAP) and other ventilation modalities. Aerosurf®, the Company's initial aerosolized KL4 surfactant product, holds the promise to significantly expand the use of surfactant therapy in at-risk premature infants by potentially providing neonatologists with a means of administering surfactant without the risks currently associated with surfactant administration. The Company believes that Aerosurf, if approved, will allow for a potentially significant increase in the number of infants who will benefit from surfactant therapy.
Discovery Labs' lead KL4 surfactant product, Surfaxin® for neonatal RDS, has been previously demonstrated to be generally safe and effective in a large multi-national Phase 3 clinical program. Surfaxin is the subject of a Complete Response letter from the U.S. Food and Drug Administration (FDA) and Discovery Labs expects to submit a complete response to the FDA in the first quarter of 2011. If approved, Surfaxin would be the first synthetic, peptide-containing surfactant for commercial use in neonatal medicine.
Surfaxin and Aerosurf are investigational drugs that have not been approved by the U.S. FDA or any other world health regulatory authorities.
haben jetzt fast track bekommen...vor einigen tagen...muss mich mal
updaten...irgendwas köchelt hier...NIH ist ja nicht irgendwer...
mal grob als quelle:
WARRINGTON, Pa., Dec. 16, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announced that the Company has been awarded Phase I of a Fast Track Small Business Innovation Research Grant (SBIR) from the National Institutes of Health (NIH) to support the development of the Company's program for aerosolizing KL4 surfactant for neonatal respiratory distress syndrome (RDS). The Company submitted a proposal, with a total budget of $2.4 million, for the development of the Company's proprietary capillary aerosol generating (CAG) device technology followed by a Phase 2a clinical trial...
R/S 1 zu 15 ABER die A/S werden in einem anderen Verhältnis gesplittet und zwar von ALT 380 Millionen zu 50 Millionen.
Kein gutes Zeichen wie ich finde.
Kurs reagiert nachbörslich empfindlich darauf : rt 0,28 Dollar nachbörslich
Discovery Laboratories, Inc. (Nasdaq: DSCO | PowerRating) today announced that it has filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation (the "Amendment") to effect a 1-for-15 share consolidation, or reverse stock split ("reverse split"), effective at 12:01 a.m. on December 28, 2010 (the "Effective Time"). In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized under the Certificate of Incorporation from 380 million to 50 million. Because the Amendment does not reduce the number of authorized shares of common stock in the same proportion as the reverse split, the effect of the Amendment is to increase the number of shares of common stock available for issuance relative to the number of shares issued and outstanding. The stockholders of Discovery Labs approved proposals authorizing the Board of Directors, in its discretion, to implement the reverse split and reduce the number of authorized shares of common stock at the Annual Meeting of Stockholders held on December 21, 2010.
http://www.tradingmarkets.com/news/press-release/...plit-1389686.html
jetzt weiss ich warum die aktie so flog...machen die einen R/S 1:15... bekannt O.K., aber:
"...Discovery Laboratories, Inc. (Nasdaq: DSCO) announced that they have filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation to effect a 1-for-15 share consolidation, or reverse stock split, effective at 12:01 a.m. on December 28, 2010.
In addition, the Amendment reduces the number of shares of common stock, par value $0.001 per share, authorized under the Certificate of Incorporation from 380 million to 50 million..."
380 mio. zu 50 mio.??? nach adam riese rechne ich bei 1:15 R/S : 380 mio. zu ca. 25 mio.;
sehe ich das richtig oder haben wir hier eine "versteckte KE" von gigantischem ausmaß??